CA2425688A1 - Extended release erythromycin derivatives - Google Patents

Extended release erythromycin derivatives Download PDF

Info

Publication number
CA2425688A1
CA2425688A1 CA002425688A CA2425688A CA2425688A1 CA 2425688 A1 CA2425688 A1 CA 2425688A1 CA 002425688 A CA002425688 A CA 002425688A CA 2425688 A CA2425688 A CA 2425688A CA 2425688 A1 CA2425688 A1 CA 2425688A1
Authority
CA
Canada
Prior art keywords
composition
long chain
host
treating
bacterial infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002425688A
Other languages
English (en)
French (fr)
Inventor
Donald J. Treacy Jr.
Edward M. Rudnic
Sandra E. Wassink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MiddleBrook Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2425688A1 publication Critical patent/CA2425688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002425688A 2000-10-13 2001-10-12 Extended release erythromycin derivatives Abandoned CA2425688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68998800A 2000-10-13 2000-10-13
US09/689,988 2000-10-13
PCT/US2001/032055 WO2002038577A2 (en) 2000-10-13 2001-10-12 Extended release erythromycin derivatives

Publications (1)

Publication Number Publication Date
CA2425688A1 true CA2425688A1 (en) 2002-05-16

Family

ID=24770642

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002425688A Abandoned CA2425688A1 (en) 2000-10-13 2001-10-12 Extended release erythromycin derivatives

Country Status (6)

Country Link
EP (1) EP1333807A4 (ja)
JP (1) JP2004528272A (ja)
AU (1) AU2002239232A1 (ja)
CA (1) CA2425688A1 (ja)
MX (1) MXPA03003146A (ja)
WO (1) WO2002038577A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8795725B2 (en) * 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108046A (en) * 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
JPS49107855A (ja) * 1973-02-03 1974-10-14
JP2528652B2 (ja) * 1987-03-30 1996-08-28 エスエス製薬株式会社 持効性セフラジン製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
JPH07267850A (ja) * 1994-03-28 1995-10-17 Eisai Co Ltd 不快味を防止した医薬組成物及びその製造方法
EP0826376B1 (en) * 1995-05-02 2007-01-24 Taisho Pharmaceutical Co. Ltd Composition for oral administration
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5780604A (en) * 1997-09-26 1998-07-14 Abbott Laboratories 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides
JP2000169364A (ja) * 1998-09-30 2000-06-20 Taisho Pharmaceut Co Ltd 経口製剤用粒子
JP4694669B2 (ja) * 1999-03-17 2011-06-08 第一三共株式会社 医薬組成物
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini

Also Published As

Publication number Publication date
MXPA03003146A (es) 2004-12-06
EP1333807A2 (en) 2003-08-13
WO2002038577A2 (en) 2002-05-16
AU2002239232A1 (en) 2002-05-21
EP1333807A4 (en) 2005-06-29
JP2004528272A (ja) 2004-09-16
WO2002038577A3 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
US8633241B2 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
KR100638307B1 (ko) ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 안정한 약학적조제물
US4743450A (en) Stabilized compositions
EP1901736B1 (en) Pharmaceutical composition comprising simvastatin and ezetimibe
US4562069A (en) Two-phase formulation
EP2041084B1 (en) Co-crystals of pyrrolidinones
EP2783688A1 (en) Pharmaceutical tablets of crystalline type ii aripiprazole
AU2000249434A1 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
JP2004501121A (ja) 安定した医薬効果を有する合成物、及びそれを含む医薬製剤
CN101528262A (zh) 药物组合物
EP1080721B1 (en) Non-crystalline solid dispersant comprising cefuromixe axetil
KR100988233B1 (ko) 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제
CA2425688A1 (en) Extended release erythromycin derivatives
CA2355239C (en) Pharmaceutical formulations
AU7863098A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
US20040157925A1 (en) Stable pharmaceutical composition of pravastatin
EP1296672B1 (en) Stable pharmaceutical product and formulation
WO2011034514A2 (en) Stable micronized granules having high solubility
SK17142000A3 (sk) Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety
MXPA98006166A (en) Pharmaceutical preparations of cilansetron stabilized against the racemizac
MXPA00011154A (en) Novel formulation containing paroxetine
MXPA00006292A (en) Hyperhydrated citicoline, process and use

Legal Events

Date Code Title Description
FZDE Dead